«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2020年06期

页码:

746-750

栏目:

出版日期:

2020-12-20

文章信息/Info

Title:

Clinical characteristics and risk factors of chronic obstructive pulmonary disease complicated with hypertension

作者:

王美菊¹; 胡明冬¹; 2; 陈华萍¹; 2; 徐 静¹; 刘双林¹; 刘 刚¹; 张文静¹; 刘 熙¹; 焦玉丁¹;  刘士琛¹;  王勤³' target='_blank'> 255);">; ?李 琦¹

400037 重庆,陆军(第三)军医大学第二附属医院呼吸与危重症医学中心¹ 老年与特勤医学科400016²? 重庆，重庆医科大学第二附属医院呼吸与危重症医学科³

Author(s):

Wang Meiju¹;  Hu Mingdong¹;  2;  Chen Huaping¹;  2;  Xu Jing¹;  Liu Shuanglin¹;  Liu Gang¹;  Zhang Wenjing¹;  Liu Xi¹;  Jiao Yuding¹;  Li Qi¹.

¹Department of Respiratory and Critical Care Medicine Center, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China; ²Department of Gerontology and Secret Service Medicine, the Second Affiliated Hospital of Army Medical University, Chongqing 400037, China

关键词:

肺疾病; 慢性阻塞性;  高血压;  合并症;  危险因素

Keywords:

Chronic obstructive pulmonary disease;  Hypertension;  Complications;  Risk factors

分类号:

-

DOI:

10.3877/cma.j.issn.1674-6902.2020.06.006

摘要:

目的 观察慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)合并高血压的临床特征,同时分析其相关的危险因素。方法 收集陆军军医大学新桥医院2016年1月至2018年12月住院的COPD合并高血压患者122例,观察COPD合并高血压的临床特征,同时以单纯COPD患者40例为对照组,应用多因素Logistic 回归分析COPD合并高血压的危险因素。结果 122例COPD合并高血压患者中,29.41%合并冠心病、22.99%合并肾疾病和糖尿病、21.39%合并肺心病、14.97%合并脑梗死、4.28%合并心绞痛、4.28%合并心肌梗死、9.63%合并其他心血管疾病。合并冠心病、心肌梗死、其他心血管疾病患者平均年龄显著高于COPD合并高血压患者对照组(P<0.05); 合并肺心病患者病程显著长于对照组(P<0.05); 合并冠心病、糖尿病、脑梗死、心绞痛、心肌梗死患者每年急性加重次数显著多余对照组(P<0.05); 合并心绞痛和其他心血管疾病患者住院时间显著长于对照组(P<0.05)。多因素Logistic 回归分析显示年龄(>80岁)、吸烟支数(>700支/年)、饮酒史、CRP(>50 mg/L)、BNP(>100 ng/L)、高血糖是COPD患者合并高血压的危险因素。结论 COPD合并高血压易引起其他相关性疾病而加重病情,及早关注其危险因素可提高患者预后。

Abstract:

Objective To explore the clinical characteristics of chronic obstructive pulmonary disease(COPD)with hypertension, and analyze the risk factors. Methods One hundred twenty-two patients with COPD and hypertension were collected from department of respiratory and critical care medicine center of Xinqiao Hospital from January 2016 to December 2018, and observed their clinical characteristics. Meanwhile, 40 COPD patients as control group, the risk factors were analyzed by multi factor Logistic regression. Results Among 122 COPD patients with hypertension, 29.41% were complicated with coronary heart disease, 22.99% with renal disease and diabetes, 21.39% with pulmonary heart disease, 14.97% with cerebral infarction, 4.28% with angina pectoris, 4.28% with myocardial infarction and 9.63% with other cardiovascular diseases. The age of patients with coronary heart disease, myocardial infarction and other cardiovascular diseases was significantly higher than that of COPD patients with hypertension(P<0.05); the disease course of with cor pulmonale was remarkably longer than that of control group(P<0.05); the number of acute exacerbations with coronary heart disease, diabetes, cerebral infarction, angina pectoris and myocardial infarction was obviously more than that in the control group(P<0.05); the hospitalization time of patients with angina pectoris and other cardiovascular diseases was significantly longer compared with control group(P<0.05). Logistic regression analysis showed that over 80 years old, smoking more than 700 per year, drinking, C-reactive protein(CRP)more than 50 mg/L, B-type brain natriuretic peptide(BNP)more than 100 ng/L, hyperglycemia were the risk factors of COPD with hypertension. Conclusion COPD complicated with hypertension often caused other related diseases and aggravated the disease. Therefore, it is necessary to pay attention to risk factors as early as possible, which will improve the prognosis of patients.

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
3 Raherison C, Ouaalaya EH, Bernady A, et al. Comorbidities and COPD severity in a clinic-based cohort[J]. BMC Pulm Med, 2018, 16, 18(1): 117.
4 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053): 1545-1602.
5 Imaizumi Y, Eguchi K, Kario K. Lung Disease and Hypertension[J]. Pulse(Basel), 2014, 2(1-4): 103-112.
6 陈华萍, 胡明冬, 张君国, 等. 慢性阻塞性肺疾病合并症及其对预后的影响[J]. 解放军医学杂志, 2020, 45(8): 834-839.
7 Global Initiative for Chronic Obstructive Lung Disease(GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease(2018 report)[R]. [2017-11-15]. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
8 Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension( ESH)and of the European Society of Cardiology(ESC)[J]. J Hypertens, 2013, 31(7): 1281-1357.
9 Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study[J]. Lancet Respir Med, 2018, 6(6): 421-430.
10 Koskela J, Kilpel?inen M, Kupiainen H, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD[J]. BMC Pulm Med, 2014, 14(1): 102.
11 Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease:impact on physical functional limitations[J]. Am J Med, 2008, 121: 789-796.
12 Hillas G, Perlikos F, Tsiligianni I, et al. Managing comorbidities in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2015, 10: 95-109.
13 Honglei Yin, Shiqi Yin, Qingyan Lin, et al. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis[J]. Medicine, 2017, 96: 19(e6836).
14 Roversi S, Roversi P. Coronary artery disease concomitant with chronic obstructive pulmonary disease[J]. Eur J Clin Invest, 2014, 44(1): 93-102.
15 Liang BM, Xu ZB. Association of chronic obstructive pulmonary disease with coronary artery disease[J]. Chin Med J, 2013, 126(17): 3205-3208.
16 Agarwal S, Rokadia H. Burden of cardiovascular disease in chronic obstructive pulmonary disease[J]. Am J Prev Med, 2014, 47(2): 105-114.
17 Ferri C. Strategies for Reducing the Risk of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease[J]. High Blood Press Cardiovasc Prev, 2015, 22(2): 103-111.
18 Choi BJ, Prasad A, Gulati R, et al. Coronary endothelial dysfunctipon in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque[J]. Eur Heart J, 2013, 34(27): 2047-2054.
19 Trostdorf F, Landgraf C, Kablau M, et al. Increased endothelial cell apoptosis in symptomatic high-grade carotid artery atenosis: preliminary data[J]. Eur J Vase Endovasc Surg, 2007, 33(1): 65-68.
20 NA Bishop, T Lu, BA Yankner, et al. Neural mechanisms of ageing and cognitive decline[J]. Nature, 2010, 464(7288): 529e535.
21 E Sibille. Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders, Dialogues Clin[J]. Neurosci, 2013, 15(1): 53e65.
22 L Lahousse, MW Vernooij, SK Darweesh, et al. Chronic obstructive pulmonary disease and cerebral microbleeds. the rotterdam study[J]. Am J Respir Crit Care Med, 2013, 188(7): 783e788.
23 Lahousse L, Tiemeier H, Ikram MA, et al. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review[J]. Respir Med, 2015, 109(11): 1371-1380.
24 Geltser BI, Kurpatov IG, Kotelnikov VN, et al. Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity[J]. Ter Arkh, 2018, 90(3): 81-88.
25 Wang W, Jiang B, Sun H, et al. Prevalence, incidence and mortality of stroke in China: results from anationwide population-based survey of 480, 687 adults[J]. Circulation, 2017, 135(8): 759-771.
26 Kim Y, Cho WK. Effects of smoking on disease risk among South Korean adults[J]. Tob Induc Dis, 2018, 16: 45.
27 Künzi L, Holt GE. Cigarette smoke activates the parthanatos pathway of cell death in human bronchial epithelial cells[J]. Cell Death Discov, 2019, 5: 127.
28 Ho TW, Huang CT, Ruan SY, et al. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality[J]. PLoS One, 2017, 12(4): e0175794.
29 Lee CT, Mao IC, Lin CH, et al. Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: a nationwide population-based study[J]. Eur J Clin Invest, 2013, 43(11): 1113-1119.
30 Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2012, 186(2): 155-161.
31 DelR Y, CabiatiM, Clerico A. Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heartfailure[J]. PharmacolRes, 2013, 76: 190.
32 Li MH, Fan LC, Mao B, et al. Short-term Exposure to Ambient Fine Particulate Matter Increases Hospitalizations and Mortality in COPD: A Systematic Review and Meta-analysis[J]. Chest, 2016, 149(2): 447-458.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金资助项目(81800084) 陆军军事医学创新工程专项(18CX2002)
通信作者: 李 琦, Email: liqioliver@sina.com 徐 静, Email: physicianxj@qq.com

常用功能

更新日期/Last Update: 2020-12-20